RheumThoughts: An Opportunity to Say Yes Hi, I am Dr. Kathryn Dao ( @KDAO2011 ) a rheumatologist and senior editor for the RheumNow Women in Rheumatology Campaign. I wanted to share you with an opportunity. An Opportunity to Say Yes. https://t.co/dJKWFAASV9 https://t.co/Cm4vn563Pz

Romania to U.S.: My Journey to a Permanent Residency One in four practicing physicians in the United States are international medical graduates. I am one of them. Dr. Maria Danila shares her IMG experience. https://t.co/vpxyosojxc https://t.co/FrIuLyvgXS

Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH

UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/0xzTobgmIQ https://t.co/YvEUMsqLyV

25 Great Women in Rheumatology This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? I'm sharing the responses. https://t.co/N1zqs3TJuv https://t.co/LXDxnXUaG9

Denosumab Reduces Type II Diabetes Risk The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/7SMjp258gX https://t.co/SAUmahwV9J

How Being a Patient Taught Me to Be a Better Doctor Dr. Marcella Ferrada ( @maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/eUHzPTjRv8 https://t.co/rTIfyLwVLY

A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/TGcFuGl4Lp https://t.co/N0bItVkHjM